Section Arrow
IMNM.NASDAQ
- Immunome
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 7.28
+0.19 (+2.68%)
Day High 
7.6799 
Prev. Close
7.09 
1-M High
9.765 
Volume 
1.22M 
Bid
7.28
Ask
7.43
Day Low
7.14 
Open
7.6 
1-M Low
6.94 
Market Cap 
616.48M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.27 
20-SMA 8.68 
50-SMA 9.59 
52-W High 25.75 
52-W Low 6.94 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.00/--
Enterprise Value
621.25M
Balance Sheet
Book Value Per Share
2.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.04M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.